{ "disease": "glioblastoma", "label": "Glioblastoma", "url": "https://usebiotransfer.org/disease/glioblastoma/", "built": "2026-09-11", "facts_hash": { "answers": "7ad8808093e3", "targets": "d66b6bd5e7c8" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-11", "trials": "2026-09-11" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "PDGFRA", "ensembl": "ENSG00000134853", "n_drug_entries": 33, "n_distinct_drugs": 32, "drugs": { "AMUVATINIB": "PHASE_2", "AVAPRITINIB": "APPROVAL", "BECAPLERMIN": "APPROVAL", "CEDIRANIB": "APPROVAL", "CRENOLANIB": "PHASE_3", "DOVITINIB": "PHASE_3", "ENMD-981693": "PHASE_2", "FAMITINIB": "PHASE_3", "FORETINIB": "PHASE_2", "ILORASERTIB": "PHASE_2", "LINIFANIB": "PHASE_3", "MASITINIB": "APPROVAL", "MIDOSTAURIN": "APPROVAL", "MOTESANIB": "PHASE_3", "NINTEDANIB": "APPROVAL", "NINTEDANIB ESYLATE": "APPROVAL", "OLARATUMAB": "APPROVAL", "ORANTINIB": "PHASE_3", "PAZOPANIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "RIPRETINIB": "APPROVAL", "SERALUTINIB": "PHASE_3", "SU-014813": "PHASE_2", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "TAK-593": "PHASE_1", "TOVETUMAB": "PHASE_2", "VATALANIB": "PHASE_3", "X-82": "PHASE_2", "XL-820": "PHASE_2", "XL-999": "PHASE_2" }, "approved": [ "AVAPRITINIB", "BECAPLERMIN", "CEDIRANIB", "MASITINIB", "MIDOSTAURIN", "NINTEDANIB", "NINTEDANIB ESYLATE", "OLARATUMAB", "PAZOPANIB", "QUIZARTINIB", "REGORAFENIB", "RIPRETINIB", "SUNITINIB", "SUNITINIB MALATE" ], "n_approved": 14, "approved_for": { "AVAPRITINIB": [ "gastrointestinal stromal tumor" ], "BECAPLERMIN": [ "Skin ulcer" ], "CEDIRANIB": [], "MASITINIB": [], "MIDOSTAURIN": [ "mast cell leukemia", "mastocytosis", "acute myeloid leukemia by FAB classification", "systemic mastocytosis", "acute myeloid leukemia" ], "NINTEDANIB": [ "idiopathic pulmonary fibrosis", "colorectal cancer", "interstitial lung disease", "systemic sclerosis", "pulmonary fibrosis" ], "NINTEDANIB ESYLATE": [ "idiopathic pulmonary fibrosis", "systemic sclerosis", "non-small cell lung carcinoma", "Interstitial pneumonitis" ], "OLARATUMAB": [ "sarcoma", "soft tissue sarcoma" ], "PAZOPANIB": [ "renal cell carcinoma", "soft tissue sarcoma", "sarcoma" ], "QUIZARTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "RIPRETINIB": [ "gastrointestinal stromal tumor" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "PTEN", "ensembl": "ENSG00000171862", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "NF1", "ensembl": "ENSG00000196712", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" } ] }, { "symbol": "CDK4", "ensembl": "ENSG00000135446", "n_drug_entries": 17, "n_distinct_drugs": 15, "drugs": { "ABEMACICLIB": "APPROVAL", "AG-24322": "PHASE_1", "ALVOCIDIB": "PHASE_3", "AT-7519": "PHASE_2", "AZD-5438": "PHASE_1", "MILCICLIB": "PHASE_2", "PALBOCICLIB": "APPROVAL", "PHA-793887": "PHASE_1", "RG-547": "PHASE_1", "RGB-286638": "PHASE_1", "RIBOCICLIB": "APPROVAL", "RONICICLIB": "PHASE_2", "TRILACICLIB": "APPROVAL", "UCN-01": "PHASE_2", "VORUCICLIB": "PHASE_1" }, "approved": [ "ABEMACICLIB", "PALBOCICLIB", "RIBOCICLIB", "TRILACICLIB" ], "n_approved": 4, "approved_for": { "ABEMACICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PALBOCICLIB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "RIBOCICLIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "TRILACICLIB": [ "small cell lung carcinoma", "myelosuppression" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MDM2", "ensembl": "ENSG00000135679", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "ALRIZOMADLIN": "PHASE_2", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CDKN2A", "ensembl": "ENSG00000147889", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [] }, { "symbol": "RB1", "ensembl": "ENSG00000139687", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "PIK3CA", "ensembl": "ENSG00000121879", "n_drug_entries": 32, "n_distinct_drugs": 31, "drugs": { "ALPELISIB": "APPROVAL", "APITOLISIB": "PHASE_2", "AZD-6482": "UNKNOWN", "BAY-1082439": "PHASE_1", "BGT-226": "PHASE_1_2", "BUPARLISIB": "PHASE_3", "COPANLISIB": "APPROVAL", "DACTOLISIB": "PHASE_3", "DS-7423": "PHASE_1", "FIMEPINOSTAT": "PHASE_2", "GEDATOLISIB": "PHASE_3", "GSK-1059615": "PHASE_1", "INAVOLISIB": "APPROVAL", "IZORLISIB": "PHASE_1_2", "OMIPALISIB": "PHASE_1", "PANULISIB": "PHASE_1", "PAXALISIB": "PHASE_2_3", "PF-04691502": "PHASE_2", "PICTILISIB": "PHASE_2", "PILARALISIB": "PHASE_2", "PKI-179": "PHASE_1", "RECILISIB": "PHASE_1", "SAMOTOLISIB": "PHASE_2", "SERABELISIB": "PHASE_2", "SF-1126": "PHASE_2", "SONOLISIB": "PHASE_2", "TASELISIB": "PHASE_3", "VOXTALISIB": "PHASE_2", "VS-5584": "PHASE_1", "WX-037": "PHASE_1", "ZSTK-474": "PHASE_1" }, "approved": [ "ALPELISIB", "COPANLISIB", "INAVOLISIB" ], "n_approved": 3, "approved_for": { "ALPELISIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "COPANLISIB": [ "follicular lymphoma", "non-Hodgkin lymphoma", "neoplasm of mature B-cells" ], "INAVOLISIB": [ "breast neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "TERT", "ensembl": "ENSG00000164362", "n_drug_entries": 2, "n_distinct_drugs": 1, "drugs": { "IMETELSTAT": "APPROVAL" }, "approved": [ "IMETELSTAT" ], "n_approved": 1, "approved_for": { "IMETELSTAT": [ "anemia", "myelodysplastic syndrome" ] }, "tractability": [ { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "MGMT", "ensembl": "ENSG00000170430", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] } ], "trials": { "by_antigen": { "EGFRvIII": { "n": 38, "n_observational": 2, "n_active": 11, "n_withdrawn": 2, "trials": [ { "nct": "NCT02861898", "title": "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04903795", "title": "BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05660369", "title": "CARv3-TEAM-E T Cells in Glioblastoma", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07326566", "title": "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480941", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551336", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07708961", "title": "Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387400", "title": "Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00458601", "title": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2018-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00626015", "title": "Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery", "status": "COMPLETED", "last_update": "2016-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00643097", "title": "Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238237", "title": "Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA", "status": "COMPLETED", "last_update": "2017-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01257594", "title": "EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01454596", "title": "CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII", "status": "COMPLETED", "last_update": "2019-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01475006", "title": "AMG 595 First-in-Human in Recurrent Gliomas", "status": "COMPLETED", "last_update": "2016-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01480479", "title": "Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2018-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498328", "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520870", "title": "Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.", "status": "COMPLETED", "last_update": "2021-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01967758", "title": "Phase I Study of Safety and Immunogenicity of ADU-623", "status": "COMPLETED", "last_update": "2018-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02209376", "title": "Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343406", "title": "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas", "status": "COMPLETED", "last_update": "2020-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02378532", "title": "The Addition of Chloroquine to Chemoradiation for Glioblastoma", "status": "COMPLETED", "last_update": "2020-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02432417", "title": "The Addition of Chloroquine to Chemoradiation for Glioblastoma,", "status": "WITHDRAWN", "last_update": "2023-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02573324", "title": "A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification", "status": "COMPLETED", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664363", "title": "EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma", "status": "TERMINATED", "last_update": "2023-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02754362", "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma", "status": "WITHDRAWN", "last_update": "2020-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844062", "title": "Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2016-07-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844439", "title": "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283631", "title": "Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM", "status": "TERMINATED", "last_update": "2021-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03296696", "title": "Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma", "status": "TERMINATED", "last_update": "2024-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726515", "title": "CART-EGFRvIII + Pembrolizumab in GBM", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04197934", "title": "WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063682", "title": "The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients", "status": "UNKNOWN", "last_update": "2021-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05187624", "title": "A Study Evaluating the Safety, Pharmacokinetic and Anti-tumor Activity of RO7428731 in Participants With Glioblastoma", "status": "COMPLETED", "last_update": "2025-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802693", "title": "A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma", "status": "UNKNOWN", "last_update": "2023-08-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244666", "title": "Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 14, "n_observational": 0, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT05660369", "title": "CARv3-TEAM-E T Cells in Glioblastoma", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480941", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551336", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01454596", "title": "CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII", "status": "COMPLETED", "last_update": "2019-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02209376", "title": "Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664363", "title": "EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma", "status": "TERMINATED", "last_update": "2023-02-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02844062", "title": "Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2016-07-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03283631", "title": "Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM", "status": "TERMINATED", "last_update": "2021-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726515", "title": "CART-EGFRvIII + Pembrolizumab in GBM", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05063682", "title": "The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients", "status": "UNKNOWN", "last_update": "2021-10-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05802693", "title": "A Study to Evaluate the Safety, Tolerance and Initial Efficacy of EGFRvIII CAR-T on Glioblastoma", "status": "UNKNOWN", "last_update": "2023-08-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244666", "title": "Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "EGFRvIII", "EGFR variant III", "EGFR vIII", "rindopepimut", "CDX-110", "Rintega" ] }, "IL13RA2": { "n": 11, "n_observational": 0, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06815029", "title": "Intracranial Genetically Modified Immune Cells (TGF\u03b2R2KO/IL13R\u03b12 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07193628", "title": "B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07544992", "title": "Locoregional Administration of Genetically Engineered Cells (EGFR/IL13R\u03b12 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02208362", "title": "Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04661384", "title": "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168423", "title": "CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973096", "title": "CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07209241", "title": "Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 11, "n_observational": 0, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06815029", "title": "Intracranial Genetically Modified Immune Cells (TGF\u03b2R2KO/IL13R\u03b12 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma", "status": "RECRUITING", "last_update": "2026-06-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07193628", "title": "B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07544992", "title": "Locoregional Administration of Genetically Engineered Cells (EGFR/IL13R\u03b12 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02208362", "title": "Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003649", "title": "IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04661384", "title": "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05168423", "title": "CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06973096", "title": "CART-EGFR-IL13Ra2 in Newly Diagnosed GBM Following Initial Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07209241", "title": "Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "IL13RA2", "IL13Ralpha2", "IL-13Ralpha2", "IL13Ra2", "interleukin-13 receptor alpha 2", "IL13 receptor alpha 2" ] }, "HER2": { "n": 9, "n_observational": 1, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT03383978", "title": "Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06058988", "title": "Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00959946", "title": "Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer", "status": "TERMINATED", "last_update": "2013-02-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109095", "title": "CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM", "status": "COMPLETED", "last_update": "2019-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02754362", "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma", "status": "WITHDRAWN", "last_update": "2020-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03389230", "title": "Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982926", "title": "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer", "status": "TERMINATED", "last_update": "2025-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109095", "title": "CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM", "status": "COMPLETED", "last_update": "2019-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03389230", "title": "Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2" ] }, "B7-H3": { "n": 13, "n_observational": 0, "n_active": 10, "n_withdrawn": 0, "trials": [ { "nct": "NCT05366179", "title": "Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05474378", "title": "B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07268053", "title": "A Phase 0/1 Clinical Trial With an Expansion Phase of GSK5764227, a B7-H3-Targeted Antibody-Drug Conjugate (ADC), in Patients With Recurrent Grade 4 Glioma and Patients With Brain Metastases", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480941", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551336", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170141", "title": "Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04077866", "title": "B7-H3 CAR-T for Recurrent or Refractory Glioblastoma", "status": "UNKNOWN", "last_update": "2022-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385173", "title": "Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma", "status": "UNKNOWN", "last_update": "2022-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241392", "title": "Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05835687", "title": "Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06691308", "title": "WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07386002", "title": "The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 11, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT05366179", "title": "Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05474378", "title": "B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480941", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551336", "title": "Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04077866", "title": "B7-H3 CAR-T for Recurrent or Refractory Glioblastoma", "status": "UNKNOWN", "last_update": "2022-12-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385173", "title": "Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma", "status": "UNKNOWN", "last_update": "2022-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241392", "title": "Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05835687", "title": "Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06691308", "title": "WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-18", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07386002", "title": "The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "B7-H3", "CD276", "omburtamab", "enoblituzumab" ] }, "GD2": { "n": 7, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06641908", "title": "Anti-GD2 ADC M3554 in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003022", "title": "Monoclonal Antibody Therapy in Treating Patients With Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2013-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445965", "title": "Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer", "status": "COMPLETED", "last_update": "2024-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170141", "title": "Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme", "status": "TERMINATED", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764537", "title": "Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "NA", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 2, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764537", "title": "Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "GD2", "dinutuximab", "hu14.18" ] }, "EphA2": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02754362", "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma", "status": "WITHDRAWN", "last_update": "2020-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05283109", "title": "ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "EphA2", "EPHA2" ] }, "CD70": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05353530", "title": "IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06946680", "title": "IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 3, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05353530", "title": "IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07523529", "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06946680", "title": "IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CD70" ] }, "CSPG4": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "CSPG4", "chondroitin sulfate proteoglycan 4", "NG2" ] }, "survivin": { "n": 10, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT05139056", "title": "Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01250470", "title": "Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma", "status": "COMPLETED", "last_update": "2017-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02455557", "title": "SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03072134", "title": "Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma", "status": "COMPLETED", "last_update": "2023-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04013672", "title": "Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence", "status": "COMPLETED", "last_update": "2024-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978727", "title": "A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163080", "title": "SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)", "status": "UNKNOWN", "last_update": "2024-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05283109", "title": "ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06524063", "title": "Targeted Survivin DC Cell Injection for the Treatment of GBM", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07715097", "title": "Survivin-Targeted Dendritic Cell (DC) Cell Injection for Newly Diagnosed Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "survivin", "BIRC5", "SurVaxM" ] } }, "by_drug": { "ABEMACICLIB": { "n": 7, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT02977780", "title": "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810544", "title": "Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02981940", "title": "A Study of Abemaciclib in Recurrent Glioblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074785", "title": "Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6", "status": "TERMINATED", "last_update": "2025-08-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04118036", "title": "Abemaciclib + Pembrolizumab In Glioblastoma", "status": "WITHDRAWN", "last_update": "2025-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "status": "COMPLETED", "last_update": "2026-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04391595", "title": "LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients", "status": "COMPLETED", "last_update": "2026-03-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AC-480": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00979173", "title": "Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma", "status": "COMPLETED", "last_update": "2014-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AEE-788": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00107237", "title": "AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2013-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00116376", "title": "Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)", "status": "COMPLETED", "last_update": "2015-11-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05432518", "title": "Pilot Trial for Treatment of Recurrent Glioblastoma", "status": "RECRUITING", "last_update": "2025-04-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00727506", "title": "BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00875433", "title": "Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours", "status": "COMPLETED", "last_update": "2013-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00977431", "title": "Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform", "status": "COMPLETED", "last_update": "2019-02-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423525", "title": "Safety Study of Afatinib for Brain Cancer", "status": "COMPLETED", "last_update": "2022-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05432518", "title": "Pilot Trial for Treatment of Recurrent Glioblastoma", "status": "RECRUITING", "last_update": "2025-04-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00727506", "title": "BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma", "status": "COMPLETED", "last_update": "2017-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00875433", "title": "Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours", "status": "COMPLETED", "last_update": "2013-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00977431", "title": "Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform", "status": "COMPLETED", "last_update": "2019-02-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423525", "title": "Safety Study of Afatinib for Brain Cancer", "status": "COMPLETED", "last_update": "2022-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AMIVANTAMAB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06632236", "title": "5G-EMERALD: Amivantamab in Malignant Brain Tumours", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AVAPRITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04908176", "title": "A Drug-drug Interaction Study of Avapritinib and Midazolam", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BUPARLISIB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01339052", "title": "Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01349660", "title": "Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2020-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01473901", "title": "A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01576666", "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01870726", "title": "Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma", "status": "TERMINATED", "last_update": "2018-05-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01934361", "title": "Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2020-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CEDIRANIB": { "n": 10, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00305656", "title": "AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2013-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00458731", "title": "Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma", "status": "COMPLETED", "last_update": "2014-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00503204", "title": "Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour", "status": "COMPLETED", "last_update": "2009-11-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00662506", "title": "Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2023-06-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00777153", "title": "Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2016-12-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00979862", "title": "Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2015-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01062425", "title": "Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2022-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01131234", "title": "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01310855", "title": "Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma", "status": "TERMINATED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02974621", "title": "Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 10, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT02800486", "title": "Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02861898", "title": "Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma", "status": "RECRUITING", "last_update": "2026-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05956821", "title": "Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age", "status": "RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00311857", "title": "Safety Study of Cetuximab, Radiotherapy and Temozolomide in Primary Glioblastoma Multiforme(GERT)", "status": "UNKNOWN", "last_update": "2006-09-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00463073", "title": "Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas", "status": "COMPLETED", "last_update": "2008-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044225", "title": "Effect of Radiation Therapy Plus Temozolomide Combined With Cilengitide or Cetuximab on the 1-year Overall Survival of Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma", "status": "TERMINATED", "last_update": "2012-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01238237", "title": "Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA", "status": "COMPLETED", "last_update": "2017-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01884740", "title": "Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22", "status": "TERMINATED", "last_update": "2022-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03603379", "title": "Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05929456", "title": "Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)", "status": "UNKNOWN", "last_update": "2023-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00004041", "title": "Gene Therapy in Treating Patients With Recurrent Malignant Gliomas", "status": "COMPLETED", "last_update": "2018-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004080", "title": "Gene Therapy in Treating Patients With Recurrent or Progressive Brain Tumors", "status": "COMPLETED", "last_update": "2009-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CRENOLANIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02626364", "title": "Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification", "status": "COMPLETED", "last_update": "2020-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01112527", "title": "PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2018-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01520870", "title": "Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.", "status": "COMPLETED", "last_update": "2021-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DACTOLISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01508104", "title": "Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2017-08-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02430363", "title": "Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475", "status": "UNKNOWN", "last_update": "2016-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01800695", "title": "Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343406", "title": "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas", "status": "COMPLETED", "last_update": "2020-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02573324", "title": "A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification", "status": "COMPLETED", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02590263", "title": "Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma", "status": "COMPLETED", "last_update": "2020-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419403", "title": "UNITE Study: Understanding New Interventions With GBM ThErapy", "status": "TERMINATED", "last_update": "2021-04-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB MAFODOTIN": { "n": 6, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01800695", "title": "Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-11-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02343406", "title": "Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas", "status": "COMPLETED", "last_update": "2020-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02573324", "title": "A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification", "status": "COMPLETED", "last_update": "2023-05-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02590263", "title": "Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma", "status": "COMPLETED", "last_update": "2020-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419403", "title": "UNITE Study: Understanding New Interventions With GBM ThErapy", "status": "TERMINATED", "last_update": "2021-04-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "DOVITINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01753713", "title": "Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma", "status": "COMPLETED", "last_update": "2017-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01972750", "title": "Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma", "status": "UNKNOWN", "last_update": "2016-04-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DS-1001B": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "EPITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03231501", "title": "HMPL-813 in Treating Patients With Glioblastoma", "status": "UNKNOWN", "last_update": "2020-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 24, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039494", "title": "Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors", "status": "COMPLETED", "last_update": "2013-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00045110", "title": "Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00054496", "title": "Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2014-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00086879", "title": "Erlotinib Compared With Temozolomide or Carmustine in Treating Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00112736", "title": "Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma", "status": "COMPLETED", "last_update": "2015-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00124657", "title": "Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma", "status": "COMPLETED", "last_update": "2015-12-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00187486", "title": "Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors", "status": "COMPLETED", "last_update": "2017-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00227032", "title": "Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme", "status": "TERMINATED", "last_update": "2012-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00274833", "title": "Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2012-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301418", "title": "Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00335764", "title": "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma", "status": "COMPLETED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00337883", "title": "A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme)", "status": "COMPLETED", "last_update": "2014-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387894", "title": "Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma", "status": "TERMINATED", "last_update": "2013-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00445588", "title": "Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2016-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00509431", "title": "Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma", "status": "COMPLETED", "last_update": "2020-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525525", "title": "Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma", "status": "COMPLETED", "last_update": "2014-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609999", "title": "Ph I Dasatinib + Erlotinib in Recurrent MG", "status": "COMPLETED", "last_update": "2014-07-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00671970", "title": "Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)", "status": "COMPLETED", "last_update": "2013-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00672243", "title": "Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme", "status": "COMPLETED", "last_update": "2013-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00720356", "title": "Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma", "status": "COMPLETED", "last_update": "2018-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01103375", "title": "Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma", "status": "TERMINATED", "last_update": "2018-08-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01110876", "title": "Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)", "status": "TERMINATED", "last_update": "2021-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01257594", "title": "EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FIMEPINOSTAT": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03893487", "title": "Fimepinostat in Treating Brain Tumors in Children and Young Adults", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FUTUXIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02540161", "title": "Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2020-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GC1118": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03618667", "title": "GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification", "status": "COMPLETED", "last_update": "2023-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEFITINIB": { "n": 11, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00014170", "title": "Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2013-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00016991", "title": "ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00025675", "title": "Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors", "status": "COMPLETED", "last_update": "2018-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00027625", "title": "Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma", "status": "COMPLETED", "last_update": "2018-06-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00042991", "title": "Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas", "status": "COMPLETED", "last_update": "2014-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00052208", "title": "Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2020-10-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085566", "title": "Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer", "status": "COMPLETED", "last_update": "2016-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00132158", "title": "ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors", "status": "COMPLETED", "last_update": "2012-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238797", "title": "A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2011-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00250887", "title": "Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research", "status": "COMPLETED", "last_update": "2007-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01310855", "title": "Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma", "status": "TERMINATED", "last_update": "2017-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDASANUTLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03158389", "title": "NCT Neuro Master Match - N\u00b2M\u00b2 (NOA-20)", "status": "COMPLETED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IDH305": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT02381886", "title": "A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02977689", "title": "Trial of IDH305 in IDH1 Mutant Grade II or III Glioma", "status": "WITHDRAWN", "last_update": "2017-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "IMETELSTAT": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01273090", "title": "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma", "status": "COMPLETED", "last_update": "2014-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01836549", "title": "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors", "status": "TERMINATED", "last_update": "2018-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 7, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04135807", "title": "Implantable Microdevice In Primary Brain Tumors", "status": "RECRUITING", "last_update": "2025-07-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095940", "title": "Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors", "status": "COMPLETED", "last_update": "2014-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099060", "title": "Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2014-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00107003", "title": "GW572016 to Treat Recurrent Malignant Brain Tumors", "status": "COMPLETED", "last_update": "2018-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00350727", "title": "Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma", "status": "COMPLETED", "last_update": "2013-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01591577", "title": "Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02101905", "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma", "status": "COMPLETED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 7, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04135807", "title": "Implantable Microdevice In Primary Brain Tumors", "status": "RECRUITING", "last_update": "2025-07-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095940", "title": "Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors", "status": "COMPLETED", "last_update": "2014-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00099060", "title": "Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2014-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00107003", "title": "GW572016 to Treat Recurrent Malignant Brain Tumors", "status": "COMPLETED", "last_update": "2018-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00350727", "title": "Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma", "status": "COMPLETED", "last_update": "2013-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01591577", "title": "Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02101905", "title": "Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma", "status": "COMPLETED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MAB-425": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01317888", "title": "Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas", "status": "UNKNOWN", "last_update": "2011-03-17", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "MDX-447": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00005813", "title": "Bispecific Antibody Plus White Blood Cells in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2011-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MOTESANIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01273090", "title": "Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma", "status": "COMPLETED", "last_update": "2014-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01836549", "title": "Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors", "status": "TERMINATED", "last_update": "2018-07-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03107780", "title": "Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer", "status": "TERMINATED", "last_update": "2025-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02977780", "title": "INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 3, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00753246", "title": "Nimotuzumab in Adults With Glioblastoma Multiforma", "status": "COMPLETED", "last_update": "2012-12-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03388372", "title": "Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma", "status": "COMPLETED", "last_update": "2018-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07707973", "title": "Nimotuzumab Combined With the Stupp Regimen for Postoperative Residual Glioblastoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NINTEDANIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01251484", "title": "BIBF 1120 in Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01380782", "title": "BIBF 1120 for Recurrent High-Grade Gliomas", "status": "COMPLETED", "last_update": "2014-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01666600", "title": "NOA-12: BIBF1120 and R-RT in Glioblastoma", "status": "TERMINATED", "last_update": "2017-11-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NINTEDANIB ESYLATE": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01251484", "title": "BIBF 1120 in Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01380782", "title": "BIBF 1120 for Recurrent High-Grade Gliomas", "status": "COMPLETED", "last_update": "2014-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01666600", "title": "NOA-12: BIBF1120 and R-RT in Glioblastoma", "status": "TERMINATED", "last_update": "2017-11-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OLARATUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00895180", "title": "Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OLUTASIDENIB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06161974", "title": "Study of Olutasidenib and Temozolomide in HGG", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03684811", "title": "A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OSIMERTINIB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT04135807", "title": "Implantable Microdevice In Primary Brain Tumors", "status": "RECRUITING", "last_update": "2025-07-23", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732352", "title": "18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05256290", "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PALBOCICLIB": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05432518", "title": "Pilot Trial for Treatment of Recurrent Glioblastoma", "status": "RECRUITING", "last_update": "2025-04-25", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01227434", "title": "A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma", "status": "TERMINATED", "last_update": "2015-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02255461", "title": "Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "status": "TERMINATED", "last_update": "2021-03-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158389", "title": "NCT Neuro Master Match - N\u00b2M\u00b2 (NOA-20)", "status": "COMPLETED", "last_update": "2023-09-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PANITUMUMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07493447", "title": "Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01017653", "title": "Panitumumab and Irinotecan for Malignant Gliomas", "status": "TERMINATED", "last_update": "2013-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02766699", "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM", "status": "COMPLETED", "last_update": "2025-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PAXALISIB": { "n": 4, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07391215", "title": "5G-PEARL: Paxalisib in Malignant Brain Tumours", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03522298", "title": "Safety, Pharmacokinetics and Efficacy of Paxalisib (GDC-0084) in Newly-diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2025-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05183204", "title": "Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma", "status": "SUSPENDED", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PAZOPANIB": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 1, "trials": [ { "nct": "NCT00350727", "title": "Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma", "status": "COMPLETED", "last_update": "2013-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00459381", "title": "Pazopanib in Treating Patients With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01392352", "title": "HYPAZ: Hypertension Induced by Pazopanib", "status": "TERMINATED", "last_update": "2020-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01931098", "title": "Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02331498", "title": "Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275558", "title": "Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma", "status": "WITHDRAWN", "last_update": "2018-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PICTILISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02430363", "title": "Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475", "status": "UNKNOWN", "last_update": "2016-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PILARALISIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01240460", "title": "Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection", "status": "COMPLETED", "last_update": "2012-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "REGORAFENIB": { "n": 7, "n_observational": 1, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT03970447", "title": "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02926222", "title": "Regorafenib in Relapsed Glioblastoma", "status": "COMPLETED", "last_update": "2022-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04051606", "title": "Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2025-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04704154", "title": "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2025-04-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05759195", "title": "Biomolecular Analysis for Predicting Response to Regorafenib", "status": "COMPLETED", "last_update": "2025-03-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06095375", "title": "Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients", "status": "COMPLETED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "RIBOCICLIB": { "n": 6, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT05843253", "title": "Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02345824", "title": "Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma", "status": "UNKNOWN", "last_update": "2018-06-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02933736", "title": "Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03355794", "title": "A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)", "status": "COMPLETED", "last_update": "2023-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "status": "COMPLETED", "last_update": "2024-05-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03834740", "title": "A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection", "status": "COMPLETED", "last_update": "2025-05-30", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "RINDOPEPIMUT": { "n": 4, "n_observational": 1, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00458601", "title": "Phase II Study of Rindopepimut (CDX-110) in Patients With Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2018-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00626015", "title": "Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery", "status": "COMPLETED", "last_update": "2016-01-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01480479", "title": "Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma", "status": "COMPLETED", "last_update": "2018-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498328", "title": "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma", "status": "COMPLETED", "last_update": "2020-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAFUSIDENIB": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB": { "n": 12, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00499473", "title": "Sunitinib in Treating Patients With Recurrent Malignant Gliomas", "status": "COMPLETED", "last_update": "2016-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00535379", "title": "SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2010-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00606008", "title": "A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma", "status": "COMPLETED", "last_update": "2012-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00611728", "title": "Ph I SU011248 + Irinotecan in Treatment of Pts w MG", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00864864", "title": "Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2016-07-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923117", "title": "Sunitinib to Treat Recurrent Brain Cancer", "status": "TERMINATED", "last_update": "2015-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01100177", "title": "Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients", "status": "COMPLETED", "last_update": "2013-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01122888", "title": "Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme", "status": "TERMINATED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441388", "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2011-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02928575", "title": "Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma", "status": "UNKNOWN", "last_update": "2016-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025893", "title": "A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2021-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275558", "title": "Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma", "status": "WITHDRAWN", "last_update": "2018-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB MALATE": { "n": 12, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00499473", "title": "Sunitinib in Treating Patients With Recurrent Malignant Gliomas", "status": "COMPLETED", "last_update": "2016-02-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00535379", "title": "SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2010-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00606008", "title": "A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma", "status": "COMPLETED", "last_update": "2012-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00611728", "title": "Ph I SU011248 + Irinotecan in Treatment of Pts w MG", "status": "COMPLETED", "last_update": "2014-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00864864", "title": "Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2016-07-07", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00923117", "title": "Sunitinib to Treat Recurrent Brain Cancer", "status": "TERMINATED", "last_update": "2015-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01100177", "title": "Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients", "status": "COMPLETED", "last_update": "2013-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01122888", "title": "Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme", "status": "TERMINATED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441388", "title": "A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2011-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02928575", "title": "Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma", "status": "UNKNOWN", "last_update": "2016-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03025893", "title": "A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme", "status": "UNKNOWN", "last_update": "2021-04-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275558", "title": "Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma", "status": "WITHDRAWN", "last_update": "2018-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TESEVATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02844439", "title": "Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2021-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOVETUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01268566", "title": "A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2017-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00441142", "title": "Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors", "status": "COMPLETED", "last_update": "2019-03-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00613054", "title": "Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma", "status": "COMPLETED", "last_update": "2012-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00613223", "title": "Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas", "status": "COMPLETED", "last_update": "2013-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00821080", "title": "Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma", "status": "COMPLETED", "last_update": "2015-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00995007", "title": "A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas", "status": "COMPLETED", "last_update": "2016-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VATALANIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00128700", "title": "Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme", "status": "COMPLETED", "last_update": "2012-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00385853", "title": "PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs", "status": "COMPLETED", "last_update": "2013-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00387933", "title": "Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma", "status": "COMPLETED", "last_update": "2015-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "VOXTALISIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00704080", "title": "A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas", "status": "COMPLETED", "last_update": "2013-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01240460", "title": "Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection", "status": "COMPLETED", "last_update": "2012-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] } } } }